ClinicalTrials.Veeva

Menu

Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.

Viatris logo

Viatris

Status and phase

Completed
Phase 4

Conditions

Urinary Incontinence

Treatments

Drug: Tolterodine ER 4 mg QD
Behavioral: OAB Patient Behavioral Training Material

Study type

Interventional

Funder types

Industry

Identifiers

NCT00230789
A6121146

Details and patient eligibility

About

To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female subjects greater than or equal to 18 years of age
  • Overactive bladder symptoms for at least 3 months
  • Previously treated with antimuscarinic OAB medications

Exclusion criteria

  • Participation in any professionally coached sessions (RN, NP, PA or PT) teaching behavioral interventions

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

Trial contacts and locations

51

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems